In another avenue of research, CTLA4 inhibition by abatacept has been employed to mitigate the risk of GVHD after traditional DLI and, in that setting, the efficacy of DLI may rely on NK cells (109, 115, 116). The gene discussed is CTLA4; the disease is graft versus host disease.